Skip to main content
Clinical Trials/JPRN-UMIN000010923
JPRN-UMIN000010923
Completed
未知

A clinical phase II study assessing the safety and efficacy of readministration of bendamustine monotherapy or bendamustine/rituximab for relapsed low grade B cell non-Hodgkin lymphoma or mantle cell lymphoma patients previously treated with bendamustine containing chemothearpy - Assessment of the safety and efficacy of bendamustine retreatment

KEIO BRB Study Group0 sites38 target enrollmentJune 17, 2013

Overview

Phase
未知
Intervention
Not specified
Conditions
low-grade B cell non-Hodgkin lymphoma, Mantle cell lymphoma
Sponsor
KEIO BRB Study Group
Enrollment
38
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 17, 2013
End Date
June 30, 2020
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
KEIO BRB Study Group

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. patients who are pregnant/female patients who are unwilling to take prevention measures for contraception during treatment 2\. patients with active cancer 3\. patients wih mental illnesses that the treating physician judges difficult to participate in the study 4\. patients with circulating tumor cells \> 25,000 /uL 5\. patients with severe allergic reaction to medication 6\. patients with active infectious diseases 7\. patients who are positive for HBs antigen or HBV\-DNA 8\. patients who are judged inadequate to participate in the study according to the treating physician

Outcomes

Primary Outcomes

Not specified

Similar Trials